The heart that cost a down payment on an apartment — now priced like a luxury car
For people with end-stage heart failure, the math is brutal. In China, an estimated 1.3 million patients are living with hearts too weak to pump blood properly. They get short of breath walking across a room, can't lie flat at night, and count their remaining time in months.
The only cure is a new heart. But across the entire country, only around 700 heart transplants happen each year.
So what happens to the other hundreds of thousands of patients?
For the past two decades, there was one expensive answer: a ventricular assist device (VAD) — a tiny implantable blood pump that does the heart's job. One American company, Abbott, held the technology. Its HeartMate 3 cost around 1.5 million yuan (about $210,000 USD) in China.
That was just for the pump. Not the surgery.
How the price got crushed: 1.5 million to 360,000 yuan
An artificial heart is one of the hardest medical devices to build. It's a magnetically levitated blood pump, surgically tucked into the chest, spinning thousands of times a minute. It has to run continuously for years without stopping — and without destroying the blood it pumps. Fewer companies on earth can do this than you can count on one hand.
For years, the market was simple: if you wanted a mature product in China, Abbott was basically your only option. A monopoly like that sets its own price — 1.5 million yuan per unit.
Then Chinese manufacturers entered.
Today, every implantable artificial heart approved in China except Abbott's is a domestic product. Five companies: BrioHealth (同心医疗), Core Medical (核心医疗), Evermag (永仁心), Terumo/Taixin (航天泰心), and XinQing (心擎医疗).
Prices moved immediately.
Take BrioHealth's CH-VAD, the fastest mover. Its average selling price fell from 459,600 yuan in 2022 to 362,300 yuan in the first half of 2025 — a drop of more than 21%.
1.5 million versus 360,000. About a quarter of the price.
Run the full totals and it looks even better: an imported artificial heart's complete treatment (pump + surgery + hospital stay) once approached 2 million yuan. Domestic versions have pulled the whole package down to the 800,000 to 1 million yuan range.
In 2024, China's National Healthcare Security Administration (NHSA) directly summoned device makers for talks. Afterward, one domestic company reported a price of 499,000 yuan — cutting the industry price by roughly 200,000 yuan.
The same year, the NHSA added standardized pricing items for VAD implantation across the country — making the billing legitimate and opening the door to insurance coverage.
Why China dared touch this 'forbidden zone'
What makes an artificial heart so hard? It's a living machine.
The pump's blades spin thousands of times per minute. If the bearings rub and generate heat, the blood burns. Magnetic levitation keeps the blades suspended in mid-air, touching nothing — a technology Abbott spent decades perfecting.
China's breakthrough path was straightforward, and aggressive.
First, go straight to third-generation full magnetic levitation. BrioHealth's CH-VAD and the upgraded CH-VAD Plus both use full maglev — no cheap bearing-based "transition" models. CH-VAD has passed 670+ clinical implants, a number that for an implantable device is credibility earned patient by patient.
Second, go small. Core Medical's Corheart 6 is the world's smallest and lightest full-maglev artificial heart. It weighs just 90 grams — about half the weight of the HeartMate 3. Smaller device, smaller incision, faster recovery. For Asian chest cavities, small isn't a luxury. It's a necessity.
Third, attack the hardest market. BrioHealth's next-generation device, BrioVAD, has won FDA approval to enter US clinical trials — the first Chinese active implantable device to knock on that door.
And they're not just defending home turf. In mid-September, Core Medical formally launched the commercial rollout of Corheart 6 in Europe — a domestic artificial heart starting to sell in Abbott's own backyard.
A track monopolized for twenty years. In five years, it became five Chinese companies circling one American one.
Some honest caveats
Before anyone books a flight, a few straight truths.
First, 360,000 yuan is still expensive. For most families, the full 800,000+ package is still a life-changing sum. The downward trend is real, but "affordable for everyone" isn't a word you can honestly use yet.
Second, 670+ implants is a cumulative clinical number. Commercial volume is only just ramping up. The US implants thousands of VADs a year; China is still climbing that curve. The number of centers and teams able to perform the surgery nationwide is only a few dozen.
Third, FDA clinical trial approval is not FDA market approval. BrioVAD still has an entire clinical trial cycle ahead before it can truly sell in the US. Variables lie ahead.
Fourth, five domestic players in one lane means the next phase is a price war and shakeout. That's not a bad thing. But "all five survive" won't be the ending.
The people who can't wait
Back to the arithmetic at the top: 1.3 million patients with end-stage heart failure, 700 transplants a year.
Between them sits a long waiting list. Many people don't die because they're untreatable. They die because they ran out of time waiting.
In that sense, an artificial heart isn't a luxury — it's a replacement for the waiting list. If the transplant doesn't come in time, implant a pump. Keep the blood flowing. Keep the person alive. In medical terms this is called "bridge to transplant," and patients who can wait comfortably can even live with the device long-term.
The machine has fallen from 1.5 million to 360,000. Every 10,000 yuan off the price puts it within reach of another group of people on that list.
Technology can't buy everything. But the price of a heart — that, technology can buy.
The next time you hear the words "artificial heart," remember this moment: a market monopolized for twenty years, pried open in a few years by five Chinese companies.
The most expensive heart is no longer the only choice.
